NASDAQ:CERO CERo Therapeutics (CERO) Stock Price, News & Analysis $2.37 -0.23 (-8.85%) Closing price 04:00 PM EasternExtended Trading$2.41 +0.04 (+1.69%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CERo Therapeutics Stock (NASDAQ:CERO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CERo Therapeutics alerts:Sign Up Key Stats Today's Range$2.35▼$2.6850-Day Range$2.60▼$8.8052-Week Range$2.35▼$895.40Volume387,328 shsAverage Volume448,218 shsMarket Capitalization$2.86 millionP/E RatioN/ADividend YieldN/APrice Target$45.00Consensus RatingModerate Buy Company Overview CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California. Read More CERo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreCERO MarketRank™: CERo Therapeutics scored higher than 71% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingCERo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCERo Therapeutics has a consensus price target of $45.00, representing about 1,763.4% upside from its current price of $2.42.Amount of Analyst CoverageCERo Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about CERo Therapeutics' stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Read more about CERo Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.33% of the float of CERo Therapeutics has been sold short.Short Interest Ratio / Days to CoverCERo Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CERo Therapeutics has recently decreased by 32.02%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCERo Therapeutics does not currently pay a dividend.Dividend GrowthCERo Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.33% of the float of CERo Therapeutics has been sold short.Short Interest Ratio / Days to CoverCERo Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CERo Therapeutics has recently decreased by 32.02%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.47 News SentimentCERo Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for CERo Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for CERO on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows1 people have added CERo Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CERo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.72% of the stock of CERo Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 29.64% of the stock of CERo Therapeutics is held by institutions.Read more about CERo Therapeutics' insider trading history. Receive CERO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CERo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CERO Stock News HeadlinesCERo Therapeutics Expands Securities Purchase Agreement3 hours ago | tipranks.comCERo Therapeutics’ CEO Chris Ehrlich to Join Stem Cell Therapy Panel at Maxim Growth Summit 2025October 15 at 8:51 AM | quiverquant.comQREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.October 16 at 2:00 AM | Paradigm Press (Ad)CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025October 15 at 8:30 AM | globenewswire.comD. Boral Capital Reaffirms "Buy" Rating for CERo Therapeutics (NASDAQ:CERO)October 15 at 2:04 AM | americanbankingnews.comCERo Therapeutics Enters Securities Purchase AgreementOctober 14 at 4:33 PM | msn.comD. Boral Capital Maintains CERo Therapeutics Holdings (CERO) Buy RecommendationOctober 14 at 6:38 AM | msn.comCERo concludes first cohort of CER-1236 trial in AMLOctober 14 at 6:38 AM | yahoo.comSee More Headlines CERO Stock Analysis - Frequently Asked Questions How have CERO shares performed this year? CERo Therapeutics' stock was trading at $120.00 on January 1st, 2025. Since then, CERO shares have decreased by 98.0% and is now trading at $2.4150. How were CERo Therapeutics' earnings last quarter? CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) announced its quarterly earnings results on Friday, August, 22nd. The company reported ($61.71) EPS for the quarter, beating analysts' consensus estimates of ($70.23) by $8.52. When did CERo Therapeutics' stock split? CERo Therapeutics's stock reverse split before market open on Friday, June 13th 2025.The 1-20 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of CERo Therapeutics? Shares of CERO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CERo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CERo Therapeutics investors own include Verve Therapeutics (VERV), Lithium Americas (LAC), NVIDIA (NVDA), Maxeon Solar Technologies (MAXN), ARM (ARM), AST SpaceMobile (ASTS) and BigBear.ai (BBAI). Company Calendar Last Earnings8/22/2025Today10/16/2025Next Earnings (Estimated)11/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CERO Previous SymbolNASDAQ:CERO CIK1870404 Webwww.cero.bio Phone215-731-9450FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Price Target for CERo Therapeutics$45.00 High Price Target$60.00 Low Price Target$30.00 Potential Upside/Downside+1,664.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.30 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-209.40% Debt Debt-to-Equity RatioN/A Current Ratio0.56 Quick Ratio0.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($41.98) per share Price / Book-0.06Miscellaneous Outstanding Shares1,205,000Free Float1,052,000Market Cap$3.07 million OptionableN/A Beta0.41 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:CERO) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The com...Huge Alerts | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.